Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Apnimed, Inc.

Ticker
APMD
Sector
Industry
Report date
November 14, 2026
Valye AI Score

29

Low visibility
Recent developments
Recent developments summary

Recent developments include Apnimed's Q2 2026 profitability, its IPO pricing, and the pending FDA decision on AD109.

Recent developments:
  • Apnimed reported a swing to Q2 profit with net income of $125.935 million and revenue of $12.08 million as of June 30, 2026 [S1].
  • The company completed an initial public offering of 12 million shares priced at $16 per share in July 2026 [N2].
  • Apnimed is awaiting an FDA decision on its AD109 treatment for obstructive sleep apnea, with a decision anticipated in February 2027 [N1].
Overview

Apnimed, Inc. is a company engaged in developing treatments for obstructive sleep apnea, notably its AD109 product. The company recently transitioned to profitability in Q2 2026 and completed an initial public offering in mid-2026. It maintains strong liquidity with a current ratio above 5 and a cash ratio near 5 as of the latest quarter. The company is awaiting a regulatory decision from the FDA on AD109, a key milestone for its business.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Apnimed, Inc. reported Q2 2026 revenue of $12.08 million and net income of $125.935 million, with strong liquidity ratios as of June 30, 2026. The company completed an IPO in July 2026 and is awaiting an FDA decision on its AD109 product for obstructive sleep apnea in February 2027.

Scenarios for APMD

Bull case model:

The company has demonstrated a swing to profitability in Q2 2026 and maintains strong liquidity, supporting ongoing operations and development. The upcoming FDA decision on AD109 represents a critical regulatory milestone that could validate its product and support commercial launch.

Bear case model:

The company is dependent on regulatory approval for AD109, and any delays or negative outcomes could impact its business prospects. Limited disclosure on broader product pipeline, market positioning, and financial metrics such as EPS and market capitalization reduces clarity on overall business risk.

Moat:

Apnimed's moat appears to be centered on its proprietary AD109 treatment for obstructive sleep apnea, which is pending FDA approval. The regulatory pathway and potential market exclusivity could provide competitive advantages if approval is granted. However, detailed information on intellectual property or competitive positioning is not disclosed.

Risks overview
Risks summary
Regulatory approval of AD109 is the primary risk factor, with significant impact on the company's future business and financial performance.
Risks details:

• Regulatory Risk: The company's business is highly dependent on FDA approval of its AD109 product for obstructive sleep apnea. Delays or denial could materially affect operations.
• Liquidity and Financial Risk: While current liquidity ratios are strong, the company’s ability to sustain operations depends on successful commercialization and further financing if needed.
• Limited Public Information: Lack of detailed sector, industry, and comprehensive financial data limits full assessment of business model and competitive landscape.

FINAL FORECAST FOR APMD

Final take one line
Apnimed, Inc. shows moderate visibility with disclosed Q2 2026 financials, recent IPO, and a key FDA decision pending on its AD109 sleep apnea treatment.
Final take 12 to 24 month view

Business trends: Transition to profitability and focus on regulatory approval of AD109.
Execution milestones: Completion of IPO and pending FDA decision in February 2027.
Key risks: Regulatory approval uncertainty and limited public disclosure on broader business details.

Valye AI Visibility Research Score

Low visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

29
LLM visibility overview
LLM Visibility known facts
  • Apnimed, Inc. reported Q2 2026 revenue of $12.08 million and net income of $125.935 million as of June 30, 2026, according to its 10-Q/A filing [S1].
  • The company had cash and cash equivalents of $172.804 million and current assets of $184.772 million against current liabilities of $35.578 million as of June 30, 2026, resulting in a current ratio of 5.19 and a cash ratio of 4.86 [S1].
  • Apnimed completed an initial public offering of 12 million shares priced at $16 per share in July 2026 [N2].
  • The company reported a swing to Q2 profit and is awaiting an FDA decision on its AD109 product for obstructive sleep apnea, with a decision anticipated in February 2027 [N1].
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-11-13 | 10-Q/A
Sources - News headlines
  • N1 | 2026-09-09 | www.nasdaq.com | Apnimed Swings To Q2 Profit, Eyes February 2027 FDA Decision On AD109 In Obstructive Sleep Apnea | https://www.nasdaq.com/articles/apnimed-swings-q2-profit-eyes-february-2027-fda-decision-ad109-obstructive-sleep-apnea
  • N2 | 2026-07-31 | www.nasdaq.com | Apnimed Prices Initial Public Offering Of 12 Mln Shares At $16 Per Share | https://www.nasdaq.com/articles/apnimed-prices-initial-public-offering-12-mln-shares-16-share
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine